# US Breathing Disorders & Treatment Market > US Breathing Disorders Treatment Market Research Report: Size, Share, Trend Analysis By Drug Type (Antibiotics, Non-Steroidal Anti-Inflammatory Drug, Cough Suppressant, Nasal Decongestant, others), By Indication (Chronic Obstructive Pulmonary Disease, Asthma, Allergic Rhinitis, Pulmonary Hypertension, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, others) and By End Users (Hospitals and Clinics, Retail Pharmacies, Online Pharmacies) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.12% - **2024:** $ 13.8 Billion - **2025:** $ 14.78 Billion - **2035:** $ 29.4 Billion - **Key Players:** Philips (NL), ResMed (AU), Medtronic (US), Boehringer Ingelheim (DE), GlaxoSmithKline (GB), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Mylan (US) **Report ID:** MRFR/Pharma/18346-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-breathing-disorders-treatment-market-19893 --- ## Market Summary ## **US Breathing Disorders Treatment Market Overview** As per MRFR analysis, the US Breathing Disorders Treatment Market Size was estimated at 10.47 (USD Billion) in 2023. The US Breathing Disorders Treatment Market Industry is expected to grow from 12.75(USD Billion) in 2024 to 26.2 (USD Billion) by 2035. The US Breathing Disorders Treatment Market CAGR (growth rate) is expected to be around 6.767% during the forecast period (2025 - 2035). ### **Key US Breathing Disorders Treatment Market Trends Highlighted** The US Breathing Disorders Treatment Market is experiencing significant trends driven by the increasing prevalence of respiratory issues such as asthma, chronic obstructive pulmonary disease (COPD), and sleep apnea among the population. Factors such as environmental pollution, smoking, and rising allergies contribute to the higher incidence of these disorders, fueling the demand for effective treatment options. Additionally, an aging population in the US is leading to a rise in age-related respiratory conditions, further driving the market. Opportunities lie in the development and integration of advanced therapies and novel drug formulations, particularly in biologics and biosimilars. The growing interest in personalized medicine presents avenues for tailored treatment plans that align with individual patient needs, enhancing overall treatment effectiveness. Moreover, the increasing adoption of telemedicine and digital health solutions in the US facilitates access to treatment, allowing patients to manage their conditions remotely. This shift can benefit those with limited mobility or those living in rural areas. Recent trends also indicate a rise in awareness campaigns and educational programs regarding breathing disorders, supported by public health initiatives, which aim to promote early diagnosis and treatment adherence. The advent of smart inhalers and connected devices enhances patient engagement and tracking of medication usage, thus improving health outcomes. As healthcare providers continue to emphasize patient-centered care, the market is likely to see a surge in innovative and efficient treatment models that cater directly to the evolving needs of patients across the United States. **** Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Breathing Disorders Treatment Market Drivers** ### **Rising Incidence of Chronic Respiratory Diseases** The US [Breathing Disorders Treatment Market](../../../reports/breathing-disorders-treatment-market-1575) Industry is significantly driven by the increasing prevalence of chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. According to the Centers for Disease Control and Prevention (CDC), asthma affects approximately 25 million people in the United States, equating to about 1 in 13 individuals. Furthermore, studies show that COPD is projected to be the third leading cause of death by 2025, with an estimated 16 million diagnosed cases currently reported. This alarming growth necessitates advanced treatment options, thus enhancing demand within the US Breathing Disorders Treatment Market Industry. Established organizations such as the American Lung Association are actively advocating for better treatment solutions, thereby increasing awareness and driving the market forward. ### **Advancements in Medical Technology** Innovative medical technology has revolutionized treatment protocols within the US Breathing Disorders Treatment Market Industry. With continuous Research and Development investments, companies are introducing advanced devices such as nebulizers, inhalers, and respiratory monitoring systems. A report from the Food and Drug Administration suggests that over 80% of the asthma inhalers sold in the US have been upgraded with smart technology features within the past decade, allowing for better disease management. This trend significantly impacts patient outcomes and promotes adherence to treatment regimens. Leading medical device companies such as Philips and ResMed are at the forefront of these technological developments, which are crucial for the market's expansion. ### **Increased Awareness and Early Diagnosis** There has been heightened awareness regarding the importance of early diagnosis and management of breathing disorders in the US. Campaigns run by various health organizations aim to educate the public on recognizing symptoms of asthma and COPD, thus leading to early intervention. The National Heart, Lung, and Blood Institute reports that a 25% increase in screening initiatives from 2018 to 2022 has led to early detection rates improving significantly. This socio-health movement catalyzes the demand for effective treatments in the US Breathing Disorders Treatment Market Industry. Organizations like the American Thoracic Society play a pivotal role in this increased awareness, thereby enhancing patient outcomes and improving market dynamics. ## **US Breathing Disorders Treatment Market Segment Insights** ### **Breathing Disorders Treatment Market Drug Type Insights** The US Breathing Disorders Treatment Market encompasses a diverse range of drug types aimed at alleviating various respiratory conditions that affect millions of Americans. This market segmentation reflects the critical need for targeted therapies that address specific symptoms and underlying causes of breathing disorders. The diversity within the breathing disorders treatment market signals an ongoing trend towards personalized medicine, where patients can be treated with more specific options tailored to their individual conditions. The market for these drug types is influenced by various healthcare dynamics, including the rising prevalence of respiratory disorders, an increasing aging population, and the growing emphasis on preventive care. Moreover, emerging research and developments continue to propel and expand treatment horizons, identifying innovative pharmaceutical solutions which align with evolving patient needs. The robust growth potential suggests ongoing investments in the development and marketing of these essential therapies will address both immediate and long-term treatment objectives for respiratory disorders across the United States. Ultimately, the interplay of these drug types in the US Breathing Disorders Treatment Market highlights their vital importance in improving patient outcomes and overall public health. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Breathing Disorders Treatment Market Indication Insights** The US Breathing Disorders Treatment Market is experiencing robust growth, driven by the escalating prevalence of respiratory conditions. Chronic Obstructive Pulmonary Disease (COPD) holds a significant share, primarily due to factors like aging demographics and rising smoking rates. Overall, these segments reflect diverse and evolving treatment needs in the US, highlighting the importance of innovation in the Breathing Disorders Treatment Market to drive successful outcomes for patients. Enhanced awareness and access to healthcare solutions create significant opportunities for growth and improvement, bolstering the market's expansion efforts. ### **Breathing Disorders Treatment Market End User Insights** The End User segment of the US Breathing Disorders Treatment Market holds considerable significance in addressing the needs of patients with respiratory conditions. Hospitals and Clinics are crucial in providing comprehensive care, including diagnostic services and treatment options for various breathing disorders such as asthma and COPD. Overall, the diversity and integration of various End Users in the US Breathing Disorders Treatment Market demonstrate a comprehensive approach to managing respiratory health, ultimately aiming to improve patient quality of life. ## **US Breathing Disorders Treatment Market Key Players and Competitive Insights** The US Breathing Disorders Treatment Market is characterized by a competitive landscape driven by the ongoing demand for innovative therapies aimed at addressing respiratory conditions such as asthma, chronic obstructive pulmonary disease, and other pulmonary disorders. With increasing incidences of these conditions, the market has experienced significant growth, attracting various pharmaceutical players striving for market share. Companies are investing heavily in research and development to introduce advanced medications and therapies, thereby enhancing their competitive position. The market's dynamics are influenced by factors such as evolving regulatory frameworks, the introduction of biologics and biosimilars, and the rising awareness of respiratory health among the population. Furthermore, collaborations between pharmaceutical companies and healthcare providers are also shaping market strategies and expanding access to treatment. ### **Key Companies Overview** #### **Teva Pharmaceutical Industries** Teva Pharmaceutical Industries has made notable strides in the US Breathing Disorders Treatment Market through a robust portfolio of generic and specialty medications that cater to various respiratory ailments. The company leverages its extensive experience and established market presence to deliver effective treatment options for patients suffering from chronic respiratory diseases. Teva's strengths include its ability to provide cost-effective therapies without compromising quality, positioning itself favorably in a competitive market increasingly focused on value-based care. The company also benefits from its wide distribution network and solid relationships with healthcare providers, ensuring that its products are accessible to a broad patient demographic. Teva's commitment to innovation is reflected in its ongoing research initiatives aimed at improving existing treatment modalities and developing new therapies that meet evolving patient needs in the US market. #### **Merck and Co** Merck and Co has a prominent position within the US Breathing Disorders Treatment Market, recognized for its commitment to advancing respiratory health through a diverse range of leading treatments and therapies. The company's key products in this space are focused on addressing chronic conditions such as asthma and COPD, utilizing cutting-edge research to deliver both efficacy and safety. Merck's strengths lie in its strong brand reputation, innovative research, and development capabilities, as well as robust partnerships within the healthcare ecosystem that enhance its market reach. The company has actively pursued mergers and acquisitions to strengthen its product pipeline and expand its presence in the respiratory therapeutic area. These strategic endeavors allow Merck to maintain a competitive edge, leading to the development of novel therapies that cater to the complexities of respiratory disorders while improving patient outcomes in the US market. ### **Key Companies in the US Breathing Disorders Treatment Market Include** ## **US Breathing Disorders Treatment Market Industry Developments** Recent developments in the US Breathing Disorders Treatment Market have showcased significant advancements, particularly in medications and devices designed for conditions like asthma and chronic obstructive pulmonary disease (COPD). Companies such as AstraZeneca and GlaxoSmithKline have ongoing initiatives aiming to enhance inhaler technology, with an increased focus on personalized medicine. The market witnessed a notable acquisition when Boehringer Ingelheim announced its purchase of a tech-focused respiratory company in November 2022, expanding its portfolio in digital health solutions related to breathing disorders. Similarly, pharmaceutical giant Merck and Co has made strides in Research and Development, particularly targeting severe asthma treatment with novel biologics. Currently, the market is experiencing growth in valuation, driven by an increasing prevalence of respiratory diseases and a rising demand for innovative treatments. The US Centers for Disease Control and Prevention reported a 5% increase in asthma prevalence over the past two years, highlighting the urgent need for improved therapeutic options. Major players like Teva Pharmaceutical Industries and Novartis are also bolstering their positions through investments in clinical trials, underscoring the competitive landscape as the market evolves towards advanced management strategies for patients with breathing disorders. ## **US Breathing Disorders Treatment Market Segmentation Insights** ### **Breathing Disorders Treatment Market Drug Type Outlook** ### **Breathing Disorders Treatment Market Indication Outlook** ### **Breathing Disorders Treatment Market End User Outlook** ## Market Drivers ### Growing Prevalence of Breathing Disorders The increasing incidence of breathing disorders in the US is a primary driver for the breathing disorders-treatment market. Conditions such as asthma, chronic obstructive pulmonary disease (COPD), and sleep apnea are becoming more common, affecting millions of individuals. According to the CDC, approximately 25 million Americans have asthma, while COPD affects around 16 million. This rising prevalence necessitates the development and availability of effective treatment options, thereby propelling market growth. The demand for innovative therapies and devices is likely to increase as healthcare providers seek to manage these conditions more effectively. Consequently, the breathing disorders-treatment market is expected to expand as pharmaceutical companies and medical device manufacturers respond to this growing need. ### Aging Population and Associated Health Issues The aging population in the US is contributing to the expansion of the breathing disorders-treatment market. As individuals age, they are more susceptible to respiratory conditions, which can lead to increased healthcare needs. By 2030, it is estimated that 20% of the US population will be over 65 years old, a demographic that often experiences higher rates of asthma and COPD. This demographic shift is likely to drive demand for specialized treatments and management strategies tailored to older adults. Healthcare providers are increasingly focusing on developing age-appropriate therapies, which may include inhalers, nebulizers, and other devices designed for ease of use. Consequently, the breathing disorders treatment market is expected to grow in response to the healthcare challenges posed by an aging population. ### Advancements in Medical Technology and Devices Advancements in medical technology and devices are significantly influencing the breathing disorders-treatment market. Innovations such as portable nebulizers, smart inhalers, and advanced continuous positive airway pressure (CPAP) machines are enhancing the management of respiratory conditions. These technologies not only improve patient compliance but also facilitate remote monitoring and data collection, allowing healthcare providers to tailor treatments more effectively. The integration of artificial intelligence and machine learning in respiratory care is also emerging, potentially leading to more personalized treatment plans. As these technologies continue to evolve, they are likely to drive growth in the breathing disorders-treatment market, as patients and providers increasingly adopt these advanced solutions to improve health outcomes. ### Increased Investment in Research and Development Investment in research and development (R&D) is a significant driver of the breathing disorders-treatment market. Pharmaceutical companies and biotech firms are allocating substantial resources to discover new therapies and improve existing treatments. In 2025, R&D spending in the healthcare sector is projected to reach over $200 billion in the US, with a considerable portion directed towards respiratory diseases. This focus on innovation is likely to yield novel medications, biologics, and advanced delivery systems, enhancing treatment efficacy. Furthermore, collaborations between academic institutions and industry players are fostering breakthroughs in understanding the underlying mechanisms of breathing disorders. As a result, the breathing disorders-treatment market is poised for growth, driven by the continuous influx of new and improved therapeutic options. ### Rising Awareness and Education on Respiratory Health There is a growing awareness and education regarding respiratory health among the US population, which is positively impacting the breathing disorders-treatment market. Public health campaigns and educational initiatives are informing individuals about the risks associated with untreated breathing disorders and the importance of early intervention. This heightened awareness is likely to lead to increased screening and diagnosis rates, resulting in a greater demand for treatment options. Additionally, healthcare providers are emphasizing the need for patient education on managing chronic conditions, which can improve adherence to treatment regimens. As a result, the breathing disorders-treatment market is expected to benefit from this trend, as more individuals seek effective therapies and management solutions for their respiratory issues. ## Future Outlook The breathing disorders-treatment market is projected to grow at a 7.12% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence, and rising healthcare expenditure. **New opportunities:** - Development of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)platforms for remote patient monitoring Investment in AI-driven diagnostic tools for early detection Expansion of home-based treatment solutions for chronic conditions By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Drug Class: Cough Suppressant (Largest) vs. Nasal Decongestant (Fastest-Growing) In the US breathing disorders-treatment market, the distribution of market share among various drug classes showcases significant variation. Cough suppressants hold the largest share due to their widespread usage in treating persistent cough associated with breathing disorders. Following closely are nasal decongestants, which, while not as dominant, are crucial in providing relief from nasal congestion, a common symptom in respiratory conditions. Other classes like antibiotics and NSAIDs contribute but to a lesser extent, indicating a competitive landscape. Growth trends indicate a robust demand for cough suppressants as incidences of respiratory conditions continue to rise. Meanwhile, nasal decongestants are emerging as the fastest-growing segment, driven by increased awareness regarding respiratory health and the escalating need for quick relief solutions. Furthermore, innovations in drug formulations and marketing strategies tailored to specific demographics significantly contribute to their rising adoption rates within the market. Cough Suppressant (Dominant) vs. Nasal Decongestant (Emerging) Cough suppressants dominate the US breathing disorders-treatment market due to their high efficacy in alleviating cough symptoms, a key concern for patients. Their strong market presence is supported by a variety of formulations, including syrups and lozenges, catering to both chronic and acute conditions. On the other hand, nasal decongestants are recognized as an emerging class, quickly gaining traction among consumers seeking immediate relief from nasal blockage. The growth of this segment is further fueled by the development of more effective and safer formulations, alongside escalating marketing efforts that emphasize rapid results and targeted benefits for allergy sufferers and those with respiratory infections. ### By Indication: Chronic Obstructive Pulmonary Disease (COPD) (Largest) vs. Asthma (Fastest-Growing) The US breathing disorders-treatment market exhibits a diverse landscape in the 'Indication' segment, with Chronic Obstructive Pulmonary Disease (COPD) dominating this space due to its high prevalence and substantial healthcare burden. Other notable segments include Asthma and Allergic Rhinitis, which also hold significant market shares, while Pulmonary Hypertension, Cystic Fibrosis (CF), Idiopathic Pulmonary Fibrosis, and Others represent smaller but crucial parts of the market. Growth trends in this segment are driven by increasing awareness of respiratory disorders, advancements in treatment options, and the rising aging population prone to COPD and Asthma. The demand for innovative therapies and personalized medicine is further bolstering the sector's expansion. Moreover, ongoing research and development activities aimed at discovering new biologics and targeted therapies indicate that the market will continue to evolve over the coming years, particularly in the Asthma segment, which is witnessing rapid growth. COPD (Dominant) vs. Asthma (Emerging) Chronic Obstructive Pulmonary Disease (COPD) remains the dominant indication in the US breathing disorders-treatment market, characterized by a high rate of hospitalization and healthcare utilization. The treatment landscape for COPD comprises bronchodilators, corticosteroids, and newer biologic therapies that enhance patients' quality of life. Meanwhile, the Asthma segment is emerging rapidly, fueled by improved awareness, effective management strategies, and a growing number of innovative therapies designed to tackle uncontrolled asthma. Both indications require continual medical attention and personalized treatment plans, but the urgent need for effective asthma management solutions has drawn significant research interest, paving the way for groundbreaking therapies that address the unmet needs of asthma patients. ### By End User: Hospitals and Clinics (Largest) vs. Online Pharmacies (Fastest-Growing) In the US breathing disorders-treatment market, the distribution of market share among different end users shows a clear predominance of hospitals and clinics, which capture a significant portion of the market due to their capability to provide comprehensive care and access to specialists. Retail pharmacies play a vital role as well, offering necessary medications, yet they do not match the market share held by hospital settings. Online pharmacies are gaining traction, yet their share remains smaller compared to traditional settings. The growth trends within the end user segment indicate a dynamic shift towards online pharmacies, which are becoming increasingly popular due to their convenience and the ability to deliver medications directly to patients. Factors driving this shift include the rise of e-commerce and changes in consumer behavior, especially following the pandemic, which has led to a greater acceptance of online healthcare solutions. Hospitals and clinics are continually adapting to this competitive landscape by integrating telehealth services, ensuring their relevance in the evolving market. Hospitals and Clinics (Dominant) vs. Online Pharmacies (Emerging) Hospitals and clinics represent the dominant force in the end user segment of the US breathing disorders-treatment market due to their comprehensive treatment offerings and the presence of specialized healthcare professionals. Their ability to conduct thorough diagnostics and provide personalized treatment plans significantly boosts their market position. Conversely, online pharmacies are emerging rapidly, driven by the growing consumer preference for convenience and accessibility in healthcare purchasing. These platforms allow patients to acquire medications without the need for physical visits, expanding access considerably. As regulations evolve to support telehealth and digital prescriptions, online pharmacies are set to capture a larger share of the market, challenging the traditional dominance of hospitals and clinics. ## Competitive Benchmarking The breathing disorders-treatment market is characterized by a dynamic competitive landscape, driven by increasing prevalence of respiratory conditions and a growing emphasis on innovative treatment solutions. Key players such as Philips (NL), ResMed (AU), and Medtronic (US) are strategically positioned to leverage advancements in technology and patient-centric approaches. Philips (NL) focuses on enhancing its product portfolio through digital health solutions, while ResMed (AU) emphasizes cloud-connected devices that facilitate remote patient monitoring. Medtronic (US) is actively pursuing partnerships to expand its reach in the market, indicating a trend towards collaborative innovation that shapes the competitive environment. In terms of business tactics, companies are increasingly localizing manufacturing to reduce supply chain vulnerabilities and optimize operational efficiency. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like GlaxoSmithKline (GB) and AstraZeneca (GB) suggests a trend towards consolidation, as these firms seek to enhance their competitive positioning through strategic mergers and acquisitions. In October 2025, Philips (NL) announced the launch of a new line of portable oxygen concentrators designed to improve mobility for patients with chronic respiratory diseases. This strategic move not only enhances Philips' product offerings but also aligns with the growing demand for portable and user-friendly medical devices, potentially increasing market penetration and customer loyalty. In September 2025, ResMed (AU) expanded its partnership with a leading telehealth provider to integrate its cloud-based solutions into remote patient management systems. This collaboration is significant as it underscores the importance of digital health in improving patient outcomes and streamlining care processes, positioning ResMed as a leader in the [digital transformation](https://www.marketresearchfuture.com/reports/digital-transformation-market-8685)of respiratory care. In August 2025, Medtronic (US) completed the acquisition of a startup specializing in AI-driven respiratory monitoring technologies. This acquisition is likely to enhance Medtronic's capabilities in predictive analytics, allowing for more personalized treatment plans and improved patient management. Such strategic actions reflect a broader trend towards integrating advanced technologies into respiratory care, which may redefine competitive dynamics in the market. As of November 2025, current trends indicate a strong focus on digitalization, sustainability, and AI integration within the breathing disorders-treatment market. Strategic alliances are increasingly shaping the landscape, fostering innovation and enhancing service delivery. The competitive differentiation is expected to evolve, shifting from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. Companies that can effectively harness these trends are likely to secure a competitive edge in the evolving market. ## Recent News & Developments Recent developments in the US Breathing Disorders Treatment Market have showcased significant advancements, particularly in medications and devices designed for conditions like asthma and chronic obstructive pulmonary disease (COPD). Companies such as AstraZeneca and GlaxoSmithKline have ongoing initiatives aiming to enhance inhaler technology, with an increased focus on personalized medicine. The market witnessed a notable acquisition when Boehringer Ingelheim announced its purchase of a tech-focused respiratory company in November 2022, expanding its portfolio in digital health solutions related to breathing disorders. Similarly, pharmaceutical giant Merck and Co has made strides in Research and Development, particularly targeting severe asthma treatment with novel biologics. Currently, the market is experiencing growth in valuation, driven by an increasing prevalence of respiratory diseases and a rising demand for innovative treatments. The US Centers for Disease Control and Prevention reported a 5% increase in asthma prevalence over the past two years, highlighting the urgent need for improved therapeutic options. Major players like Teva Pharmaceutical Industries and Novartis are also bolstering their positions through investments in clinical trials, underscoring the competitive landscape as the market evolves towards advanced management strategies for patients with breathing disorders. ## Report Scope | MARKET SIZE 2024 | 13.8(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 14.78(USD Billion) | | MARKET SIZE 2035 | 29.4(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.12% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Philips (NL), ResMed (AU), Medtronic (US), Boehringer Ingelheim (DE), GlaxoSmithKline (GB), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Mylan (US) | | Segments Covered | Drug Class, Indication, End User | | Key Market Opportunities | Integration of telehealth solutions enhances access to breathing disorders-treatment services. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the breathing disorders-treatment market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US breathing disorders-treatment market in 2024?** A: The market valuation was $13.8 Billion in 2024. **Q: What is the projected market valuation for the US breathing disorders-treatment market by 2035?** A: The projected valuation for 2035 is $29.4 Billion. **Q: What is the expected CAGR for the US breathing disorders-treatment market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 7.12%. **Q: Which drug class had the highest market value in 2024, and what was that value?** A: The 'Others' category in drug class had the highest market value at $7.57 Billion in 2024. **Q: What are the projected values for Chronic Obstructive Pulmonary Disease (COPD) treatment by 2035?** A: The projected value for COPD treatment is $11.66 Billion by 2035. **Q: Which end user segment is expected to grow the most from 2024 to 2035?** A: The 'Hospital and Clinics' segment is expected to grow from $5.52 Billion in 2024 to $12.0 Billion by 2035. **Q: What is the market value for asthma treatment in 2024?** A: The market value for asthma treatment was $3.45 Billion in 2024. **Q: Which key players are leading the US breathing disorders-treatment market?** A: Key players include Philips, ResMed, Medtronic, Boehringer Ingelheim, and GlaxoSmithKline. **Q: What is the projected market value for online pharmacies by 2035?** A: The projected market value for online pharmacies is $8.9 Billion by 2035. **Q: What was the market value for antibiotics in 2024?** A: The market value for antibiotics was $2.07 Billion in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-breathing-disorders-treatment-market-19893*